Crown Bioscience raises $28.8M to boost CRO activities for preclinical cancer biology work
This article was originally published in Scrip
Executive Summary
Crown Bioscience, a CRO providing biological expertise to advance pre-IND programmes in the oncology area, has raised $28.8 million in a third round of venture financing. CrownBio co-founder and CEO Alex Wu claims that the funding positions the company "to take advantage of the fast growing global outsourcing market".